Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Primary endpoint met in phase IIb study of clazakizumab for rheumatoid arthritis

May 6, 2015

Shanghai Yingli patents PI3Kdelta inhibitors

April 30, 2015

Facio Therapies and Evotec to discover drugs for facioscapulohumeral dystrophy

April 30, 2015

Galapagos's filgotinib meets primary endpoint in phase II trial in rheumatoid arthritis

April 29, 2015

Uric acid as a novel predictive biomarker in ankylosing spondylitis

April 22, 2015

Ampio reports results from phase III trial STRIDE of Ampion in OA

April 21, 2015

Lilly reports phase III trial success with ixekizumab

April 21, 2015

Anika Therapeutics completes enrollment in repeat-injection study of Cingal

April 21, 2015

Primary endpoint met in phase IIb trial of JAK1 inhibitor for rheumatoid arthritis

April 16, 2015

Novel thienopyrimidinone PDE7 inhibitors discovered at Kaken

April 16, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....